Descriptions and interpretations of the ACCORD-lipid trial in the news and biomedical literature: A cross-sectional analysis

JAMA Internal Medicine

Volumn 174, Issue 7, 2014, Pages 1176-1182

  Downing, Nicholas S ^a   Cheng, Theresa ^b   Krumholz, Harlan M ^a,c   Shah, Nilay D ^d   Ross, Joseph S ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; CONFLICT OF INTEREST; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STATISTICS;

CARDIOVASCULAR DISEASES; CONFLICT OF INTEREST; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; EVIDENCE-BASED MEDICINE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 84904128310     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.1371     Document Type: Article

References (27)

1. ACCORD Study Group; Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12A):21i-33i. doi:10.1016/j.amjcard.2007.03.003.
2. Ginsberg HN, Elam MB, Lovato LC, et al ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
3. Scott R, O'Brien R, Fulcher G, et al Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32(3):493-498.
4. Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-1861.
5. AbbVie. 2012 Annual report on form 10-K and 2013 proxy statement. http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-reportsannual. Accessed January 17, 2014.
6. Abbott Laboratories. 2011 Annual report on form 10-K and 2012 proxy statement. http://media.corporate-ir.net/media-files/irol/94/94004/Proxy-Page/ AR2011.pdf. Accessed January 17, 2014.
7. Downing NS, Ross JS, Jackevicius CA, Krumholz HM. Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise. Arch Intern Med. 2012;172(9):724-730.
8. National Heart, Lung, and Blood Institute. Questions and answers: Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. March 15, 2010. http://www.nhlbi.nih.gov/health/prof/heart/other/accord/q-a.htm. Accessed January 17, 2014.
9. Wang AT, McCoy CP, Murad MH, Montori VM. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ. 2010;340:c1344. doi:10.1136/bmj.c1344.
10. Srikanth S, Deedwania P. Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus. Cardiol Clin. 2011;29(1):47-70.
11. Siegel D, Swislocki ALM. The ACCORD Study: the devil is in the details. Metab Syndr Relat Disord. 2011;9(2):81-84.
12. Ismail-Beigi F. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial - clinical implications. Clin Chem. 2011;57(2):261-263.
13. Mohiuddin SM, Thakker KM, Setze CM, Kelly MT. Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Curr Med Res Opin. 2011;27(5):1067-1078.
14. Peter R, Reilly E, Anthony S. Therapy and clinical trials: fibrate therapy in type 2 diabetes - where are we now? Curr Opin Lipidol. 2010;21(6):554-555.
15. Nissen SE. Atherosclerosis in 2010: new therapeutic insights. Nat Rev Cardiol. 2011;8(2):70-72.
16. AstraZeneca. AstraZeneca and Abbott extend relationship to include co-promotion of Trilipix. http://www.astrazeneca.com/Media/Press-releases/ Article/20090604-AstraZeneca-and-Abbott-Extend-Relationship-to-Include. Published June 4, 2009. Accessed January 17, 2014.
17. US Food and Drug Administration. New drug application 019304, label and approval history: Lipidil (fenofibrate). http://www.accessdata.fda.gov/ drugsatfda-docs/nda/pre96/019304-s000.pdf. Published December 31, 1993. Accessed January 17, 2014.
18. Bloomberg. Solvay to buy Fournier for as much as EU1.6 billion (update 4). http://www.bloomberg.com/apps/news?pid=newsarchive&sid= aKiXJ38hfMBw&refer=europe. Published March 24, 2005. Accessed January 17, 2014.
19. Neuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ. 2011;343:d5621. doi:10.1136/bmj.d5621.
20. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 2010;7(9):e1000326. doi:10.1371/journal.pmed.1000326.
21. Ioannidis JP. Mega-trials for blockbusters. JAMA. 2013;309(3):239-240.
22. American Diabetes Association. Position statements. http://professional. diabetes.org/ResourcesForProfessionals.aspx?cid=91471. Accessed January 17, 2014.
23. American College of Cardiology. Guidelines and quality standards. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality- Standards.aspx. Accessed January 17, 2014.
24. Miller M, Stone NJ, Ballantyne C, et al American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292-2333.
25. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12:MR000033. doi:10.1002/14651858.MR000033.pub2.
26. Norris SL, Holmer HK, Ogden LA, Selph SS, Fu R. Conflict of interest disclosures for clinical practice guidelines in the national guideline clearinghouse. PLoS One. 2012;7(11):e47343. doi:10.1371/journal.pone.0047343.
27. Okike K, Kocher MS,Wei EX, Mehlman CT, BhandariM. Accuracy of conflict-of-interest disclosures reported by physicians. N Engl J Med. 2009;361(15):1466-1474.